Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News Alert: FDA approves first TAVR system for aortic regurgitation

News You Need to Know Today
News Alert: FDA approves first TAVR system for aortic regurgitation
Wednesday, March 18, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA approves JenaValve TAVR system for aortic regurgitation

The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis. 

READ MORE >
jenavalve TAVR valve for aortic regurgitation acquired by Edwards
Share on Twitter Share on Facebook Share on Linkedin

FDA approves JenaValve TAVR system for aortic regurgitation

Share on Twitter Share on Facebook Share on Linkedin
jenavalve TAVR valve for aortic regurgitation acquired by Edwards
The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Hypertension | April 2020
Month in Review: 10 Trending Stories from March
Acute Coronary Syndrome | March 2020
Risk of death jumps when COVID-19 patients have CVD & myocardial injury | Stories from the front lines of the pandemic
Week in Review: Cardiac injury & COVID-19 | The pandemic's impact on healthcare workers | How statins can reduce HF risk
Caring for COVID-19 patients leads to depression, distress for healthcare workers | More cardiology conferences canceled
Coronary Intervention & Surgery | March 2020

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …345
    • Page 346
    • Page 347
    • Page 348
    • Page 349
    • Current page 350
    • Page 351
    • Page 352
    • Page 353
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup